George Millen: Unscripted

Zoetis boosts its dividend by 6%, but what does this move signal about the company's financial health and the booming global animal care market?

Dynex's routine dividend declaration reveals a complex strategy of risk management and capital allocation, offering a masterclass in navigating mREIT turbulence.

With leadership buying shares and promising trial data for its novel cancer drug, MAIA Biotechnology is sending strong signals to investors. What's next?

How TerraVest's aggressive acquisition spree is reshaping industrial markets and delivering substantial returns to shareholders. Dive into the strategy.

Nasdaq-listed Caliber moves beyond passive holding, staking 75,000 LINK to actively generate yield. A look at the high-stakes strategy bridging Wall Street and Web3.

SSC's 37th dividend payment signals stability, but high payout ratios raise questions. Is management's growth-and-buyback strategy the right bet?

An energy services giant just sold its nuclear arm to a startup in a stock deal. It's a strategic pivot to mass-produce reactors for the AI power crunch.

Copper Quest diversifies from copper, acquiring a high-grade gold mine and adding 150+ years of mining expertise to its board and advisory team.

Impressive new trial data for MDNA11 could disrupt the multi-billion dollar immunotherapy market, offering real hope where standard treatments now fail.

Exodus is using its Bitcoin treasury to buy a payments firm, but declining user metrics and a change in disclosure raise questions about this bold strategy.

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

Groundbreaking lymphoma data and a strategic acquisition position Natera to dominate the liquid biopsy market, challenging old standards and creating new value.

Facing an OSC probe and audit delays, the legal tech firm is now seeking court relief, raising red flags for investors about its governance and finances.

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.

With its CFO departing after a major strategic pivot, AAR CORP. names a 13-year insider as his interim replacement. What does this signal for investors?

The battery innovator secures fresh capital to scale its 'One-Pot' process. We analyze if this move signals a turning point for investors and the EV market.

Tile Shop is delisting from Nasdaq, forcing a cash-out for small investors. We analyze the high-stakes maneuver to save millions and what it signals.

A landmark deal creates Canada's largest private brokerage. We analyze the PE-backed strategy, the 'Canadian Champion' gambit, and what it means for the market.

LAMY's all-stock deal for Exousia AI is more than a merger; it's a strategic coup built on an early FDA designation for a novel brain cancer therapy.

Gelteq is pitching its innovative drug delivery gel to investors. But with a 'going concern' warning, can its promising tech secure the cash it needs to survive?